References
- Lee KK, Cho H, Chi H, Kim DY, Chae SL, Huh HJ. A Case of postessential thrombocythemia myelofibrosis with severe osteosclerosis. Korean J Lab Med. 2010;30:122-125. https://doi.org/10.3343/kjlm.2010.30.2.122
- Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005;105:4187-4190. https://doi.org/10.1182/blood-2005-03-1287
- Ma W, Kantarjian H, Zhang X, Yeh C, Zhang Z, Verstovsek S, et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009;11:49-53. https://doi.org/10.2353/jmoldx.2009.080114
- Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061. https://doi.org/10.1016/S0140-6736(05)71142-9
- Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005;19:1847-1849. https://doi.org/10.1038/sj.leu.2403902
- Wang J, Zhang B, Chen B, Zhou R, Zhang Q, Li J, et al. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia. Hematology. 2017;22:145-148. https://doi.org/10.1080/10245332.2016.1252003
- Kim BH, Cho YU, Bae MH, Jang S, Seo EJ, Chi HS, et al. JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis. J Korean Med Sci. 2015;30:882-888. https://doi.org/10.3346/jkms.2015.30.7.882
- Kim SY, Im K, Park SN, Kwon J, Kim J, Lee DS. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol. 2015;143:635-644. https://doi.org/10.1309/AJCPUAAC16LIWZMM
- Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, et al. The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Pathol. 2015;144:165-171. https://doi.org/10.1309/AJCPALP51XDIXDDV
- Lang T, Nie Y, Wang Z, Huang Q, An L, Wang Y, et al. Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics. J Int Med Res. 2018;46:4650-4659. https://doi.org/10.1177/0300060518787719
- Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379-2390. https://doi.org/10.1056/NEJMoa1311347
- Vainchenker W, Constantinescu SN, Plo I. Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000 Research. 2016;5:1-13. https://doi.org/10.12688/f1000research.8081.1
- Ji L, Qian M, Wu N, Wu J. Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia. Exp Ther Med. 2017;13:947-951. https://doi.org/10.3892/etm.2017.4077
- Wu Z, Zhang X, Xu X, Chen Y, Hu T, Kang Z, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol. 2014;7:1-10. https://doi.org/10.1186/1756-8722-7-1
- Kim HR, Choi HJ, Kim YK, Kim HJ, Shin JH, Suh SP, et al. Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms. PLoS ONE. 2013;8:e52518. https://doi.org/10.1371/journal.pone.0052518
- Ojeda MJ, Bragos IM, Calvo KL, Williams GM, Carbonell MM, Pratti AF. CALR, JAK2 and MPL mutation status in argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology. 2018;23:208-211. https://doi.org/10.1080/10245332.2017.1385891
- Syeed N. JAK2 and Beyond: JAK2V617 mutational study of myeloproliferative disorders and haematological malignancies. Asian Pac J Cancer Prev. 2019;20:3611-3615. https://doi.org/10.31557/APJCP.2019.20.12.3611
- Jaradat SA, Khasawneh R, Kamal N, Matalka I, Al-Bishtawi M, Al-Sweedan S, et al. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2015;8:160-166. https://doi.org/10.1016/j.hemonc.2015.07.004
- Nancy LM, Samantha GB, Javier GE, Perla CP, Valeria GO, Virginia RN, et al. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2015;8:16-21. https://doi.org/10.1016/j.hemonc.2014.12.002
- Vu HA, Thao TT, Dong CV, Vuong NL, Chuong HQ, Van PNT, et al. Clinical and hematological relevance of JAK2V617F, CALR, and MPL mutations in Vietnamese patients with essential thrombocythemia. Asian Pac J Cancer Prev. 2019;20:2775-2780. https://doi.org/10.31557/APJCP.2019.20.9.2775
- Li MY, Chao HY, Sun AN, Qiu HY, Jin ZM, Tang XW, et al. Clinical significance of JAK2, CALR, and MPL gene mutations in 1648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center. chinese Journal of Hematology. 2017;38:295-300. https://doi.org/10.3760/cma.j.issn.0253-2727.2017.04.007
- Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, et al. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018;107:673-680. https://doi.org/10.1007/s12185-018-2421-7
- Geduk A, Atesoglu EB, Tarkun P, Mehtap O, Hacihanefioglu A, Demirsoy ET, et al. The role of beta-catenin in Bcr/Abl negative myeloproliferative neoplasms: an immunohistochemical study. Clin Lymphoma Myeloma Leuk. 2015;15:785-789. https://doi.org/10.1016/j.clml.2015.08.084
- Gardner JA, Peterson JD, Turner SA, Soares BL, Lancor CR, Dos Santos LL, et al. Detection of CALR mutation in clonal and non clonal hematologic diseases using fragment analysis and next-generation sequencing. Am J Clin Pathol. 2016;146:448-455. https://doi.org/10.1093/ajcp/aqw129
- Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, et al. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017;10:2-8. https://doi.org/10.1186/s13045-017-0425-z
- Xu W, Li JY, Xia J, Zhang SJ, Fan L, Qiao C. MPL W515L mutation in Chinese patients with myeloproliferative diseases. Leuk Lymphoma. 2008;49:955-958. https://doi.org/10.1080/10428190802035966
- Chen X, Qi X, Tan Y, Xu Z, Xu A, Zhang L, et al. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms. Blood Cells Mol Dis. 2011;47:67-71. https://doi.org/10.1016/j.bcmd.2011.04.004
- Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T, et al. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes. Intern Med. 2011;50:2557-2561. https://doi.org/10.2169/internalmedicine.50.5429
- Smaili W, Doubaj Y, Laarabi FZ, Lyahyai J, Kerbout M, Mikdame M, et al. CALR gene mutational profile in myeloproliferative neoplasms with nonmutated JAK2 in Moroccan patients: a case series and germline in-frame deletion. Curr Res Transl Med. 2017;65:15-29. https://doi.org/10.1016/j.retram.2016.08.002
- Schnittger S, Bacher U, Eder C, Dicker F, Alpermann T, Grossmann V, et al. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Haematologica. 2012;97:1582-1585.